Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy
复制标题
Mogamulizumab 治疗晚期蕈样肉芽肿和 Sézary 综合征的安全性和有效性
DOI：
--
复制
发表时间：
2020
影响因子：
3.3
通讯作者：
A. Rook
中科院分区：
文献类型：
--
作者：
D. Lewis;A. Rook
摘要前言：晚期真菌样肉芽肿(MF)和S综合征(SS)是一种预后较差的皮肤T细胞淋巴瘤。治疗与高复发率相关，因此存在对新的、改进的治疗方法的未得到满足的医学需求。Mogamulizumab是一种针对C-C趋化因子受体4的新型脱糖单抗，可通过抗体依赖的细胞毒作用(ADCC)消除恶性细胞。涉及mogamulizumab的I-III期临床试验证明了其显著的疗效和耐受性。在第三阶段MAVORIC研究中，莫伽慕珠单抗对晚期、复发/难治性MF/SS的疗效优于伏立诺(有效率分别为28%和5%；中位无进展生存期分别为7.7个月和3.1个月)。反应持久(中位数为14.1个月)，SS组(37%)和血室内(68%)的应答率最高。常见的不良反应包括输液反应和药疹。该药物还增加了免疫介导的并发症的风险，如移植后的自身免疫性疾病和急性移植物抗宿主病。专家认为，Mogamulizumab是治疗晚期MF/SS的一种有价值的疗法，因为它可以产生长期的反应，特别是在外周血中。由于它通过ADCC消除恶性T细胞，将莫伽珠单抗与免疫治疗药物如干扰素、白细胞介素12和Toll样受体激动剂联合使用可能会进一步增强其疗效。
ABSTRACT Introduction Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T-cell lymphoma characterized by a poor prognosis. Treatments are associated with high rates of relapse, and thus there exists an unmet medical need for new, improved therapies. Mogamulizumab is a novel defucosylated monoclonal antibody targeting C–C chemokine receptor 4 that eradicates malignant cells via antibody-dependent cellular cytotoxicity (ADCC). Areas covered Phase I–III clinical trials involving mogamulizumab demonstrated its significant efficacy and tolerability. In the phase III MAVORIC study, mogamulizumab exhibited greater efficacy than vorinostat (response rate, 28% versus 5%; median progression-free survival, 7.7 versus 3.1 months, respectively) for advanced, relapsed/refractory MF/SS. Responses were durable (median, 14.1 months), and response rates were highest in SS (37%) and within the blood compartment (68%). Common adverse events include infusion reactions and drug eruptions. The drug also increases the risk of immune-mediated complications such as autoimmune disease and acute graft-versus-host disease following transplantation. Expert opinion Mogamulizumab represents a valuable therapy for advanced MF/SS as it can produce prolonged responses, particularly within the peripheral blood. Since it eliminates malignant T cells via ADCC, combining mogamulizumab with immunotherapeutic agents such as interferons, interleukin-12, and Toll-like receptor agonists may further enhance its efficacy.
登录
查看更多内容
影响因子：
20.3
作者：
Duvic, Madeleine;Talpur, Rakshandra;Frankel, Stanley R.
通讯作者：
Frankel, Stanley R.
IL-12 可逆转塞扎里综合征中的细胞因子和免疫异常。
DOI：
--
发表时间：
1995
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Rook,AH;Kubin,M;Cassin,M;Vonderheid,EC;Vowels,BR;Wolfe,JT;Wolf,SF;Singh,A;Trinchieri,G;Lessin,SR
通讯作者：
Lessin,SR
影响因子：
20.3
作者：
Rook, Alain H.;Gelfand, Joel C.;Clark, Rachael A.
通讯作者：
Clark, Rachael A.
影响因子：
45.3
作者：
Duvic, Madeleine;Tetzlaff, Michael T.;Talpur, Rakhshandra
通讯作者：
Talpur, Rakhshandra
白细胞介素 12 治疗皮肤 T 细胞淋巴瘤可诱导病变消退和细胞毒性 T 细胞反应。
影响因子：
20.3
作者：
Rook,AH;Wood,GS;Yoo,EK;Elenitsas,R;Kao,DM;Sherman,ML;Witmer,WK;Rockwell,KA;Shane,RB;Lessin,SR;Vonderheid,EC
通讯作者：
Vonderheid,EC